Source: Brazilian Journal of Pharmaceutical Sciences. Conference titles: Pharmaceutical Science and Technology Meeting of the Faculty of Pharmaceutical Sciences, University of São Paulo. Unidade: FCF
Subjects: FÁRMACOS (METABOLISMO E NUTRIÇÃO), DIABETES MELLITUS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LUZ, Gabriella da Silva et al. Diabetic ketoacidosis in patients treated with sodium-glucose cotransporter 2 (sglt-2) inhibitor drugs: the off-label use risk. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. . Acesso em: 23 maio 2024. , 2017APA
Luz, G. da S., Ribeiro, A., Ribeiro, E., & Kazue, K. E. (2017). Diabetic ketoacidosis in patients treated with sodium-glucose cotransporter 2 (sglt-2) inhibitor drugs: the off-label use risk. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo.NLM
Luz G da S, Ribeiro A, Ribeiro E, Kazue KE. Diabetic ketoacidosis in patients treated with sodium-glucose cotransporter 2 (sglt-2) inhibitor drugs: the off-label use risk. Brazilian Journal of Pharmaceutical Sciences. 2017 ; 53 48 res. FCF092.[citado 2024 maio 23 ]Vancouver
Luz G da S, Ribeiro A, Ribeiro E, Kazue KE. Diabetic ketoacidosis in patients treated with sodium-glucose cotransporter 2 (sglt-2) inhibitor drugs: the off-label use risk. Brazilian Journal of Pharmaceutical Sciences. 2017 ; 53 48 res. FCF092.[citado 2024 maio 23 ]